Cue Biopharma, Inc. Shareholders' Equity
Cue Biopharma, Inc. (CUE) had Shareholders' Equity of $2.31 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-14
- 2026-06-30: Stockholders' Equity Attributable to Parent $2.31M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $21.61M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $26.43M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $13.25M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $2.31M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $21.61M 10-Q · filed 2026-08-14 | |
| 2025-12-31 | $26.43M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $13.25M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $18.16M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $6.58M 10-Q · filed 2026-08-14 | |
| 2024-12-31 | $17.50M 10-Q · filed 2026-08-14 | |
| 2024-09-30 | $25.37M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $21.62M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $30.04M 10-Q · filed 2025-08-12 | |
| 2023-12-31 | $37.09M 10-K · filed 2026-03-16 | |
| 2023-09-30 | $42.67M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $46.00M 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $55.02M 10-Q · filed 2024-08-14 | |
| 2022-12-31 | $65.68M 10-K · filed 2025-03-31 | $65.68M 10-K · filed 2023-03-21 |
| 2022-09-30 | $50.76M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $59.76M 10-Q · filed 2023-11-03 | |
| 2022-03-31 | $64.67M 10-Q · filed 2023-08-08 | |
| 2021-12-31 | $65.49M 10-K · filed 2024-03-28 | $65.49M 10-K · filed 2022-03-16 |
| 2021-09-30 | $63.52M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $72.91M 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $69.67M 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $78.91M 10-K · filed 2023-03-21 | |
| 2020-09-30 | $87.55M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $80.15M 10-Q · filed 2021-11-09 | |
| 2020-03-31 | $45.24M 10-Q · filed 2021-08-09 | |
| 2019-12-31 | $54.58M 10-K · filed 2022-03-16 | |
| 2019-09-30 | $27.02M 10-Q · filed 2020-11-09 | |
| 2019-07-01 | $20.28M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $20.28M 10-Q · filed 2020-11-09 | $20.28M 10-Q · filed 2019-08-08 |
| 2019-04-01 | $24.74M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $24.74M 10-Q · filed 2020-08-07 | $24.74M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $33.97M 10-K · filed 2021-03-09 | |
| 2018-09-30 | $39.40M 10-Q · filed 2019-11-07 | |
| 2018-07-01 | $49.23M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $49.23M 10-Q · filed 2019-08-08 | |
| 2018-04-01 | $55.26M 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $55.24M 10-Q · filed 2019-05-08 | |
| 2017-12-31 | $61.61M 10-K · filed 2020-03-12 | $61.61M 10-Q · filed 2018-05-14 |
| 2016-12-31 | $15.18M 10-Q · filed 2020-08-07 | $15.17M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |